Atomwise pursues 15 collaborations for COVID-19 treatments

By The Science Advisory Board staff writers

May 22, 2020 -- Small molecule drug discovery company Atomwise has announced it is collaborating with 15 institutions to develop broad-spectrum therapies for coronaviruses, including the novel coronavirus responsible for COVID-19.

Participating institutions include the following:

University of Mannitoba
Columbia University
University of Connecticut
University of Kentucky
University of South Australia
University of Texas Medical Branch Health
Jazan University
Dana-Farber Cancer Institute
University of Texas Health Science Center at San Antonio
University of Toledo

If you like this content, please share it with a colleague!

Related Reading

AGC to manufacture Takara Bio's COVID-19 vaccine
In the fight against COVID-19, AGC Biologics, a contract development and manufacturing organization, is partnering with Takara Bio to manufacture plasmid...

New platform includes biological similarities to accelerate drug discovery
A new open-access tool provides information on the effects of nearly 1 million compounds in a wide range of biological settings. The new tool, published...

Bharat, TJU partnering on COVID-19 vaccine
Bharat Biotech and Thomas Jefferson University (TJU) of Philadelphia have signed a deal to develop a new vaccine for COVID-19.

Human enzymes are implicated in SARS-CoV-2 evolution and spread
Two human deaminase enzymes that edit viral RNA inside cells could have implications for the evolution of SARS-CoV-2 and the spread of the infection,...